Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29998145 | 1.00 | CYP2D6 (0.38) | CYP2D6TSHRITGA4ITGB7ATM | |
| SCHEMBL23459316 | 0.89 | SMN1; SMN2 (0.40) | CYP2D6ATMHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL25697961 | 0.83 | ATM (0.44) | CYP2D6TSHRITGA4ITGB7ATM | |
| SCHEMBL29997800 | 0.83 | ATM (0.44) | CYP2D6TSHRITGA4ITGB7ATM | |
| SCHEMBL23528214 | 0.83 | ATM (0.44) | CYP2D6TSHRITGA4ITGB7ATM | |
| SCHEMBL29997324 | 0.82 | CYP2D6 (0.43) | CYP2D6TSHRHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL29997790 | 0.82 | CYP2D6 (0.43) | CYP2D6TSHRHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL29997825 | 0.81 | CYP2D6 (0.42) | CYP2D6TSHRITGA4ITGB7ATM | |
| SCHEMBL12979137 | 0.78 | ALDH1A1 (0.37) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL24411299 | 0.78 | ALDH1A1 (0.37) | TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4069366-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | ATM, CHEK2, CHEK1 | CYP2D6 4579/4885TSHR 3766/4885ITGA4 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.